SARS-CoV-2 Neutralizing Antibody Therapies: Early retrospective cohort study of 26 hospitalized patients treated with Bamlanivimab or Casirivimab/Imdevimab.

REGEN-COV (casirivimab/imdevimab) - Regeneron, Roche

bamlanivimab (LY-CoV555) - Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases

http://www.ncbi.nlm.nih.gov/pubmed/36690138

Jan 24, 2023